The burden of scientific progress: Growing inequalities in the delivery of cancer care

摘要: Novel targeted therapies are now a reality in oncology. The monoclonal antibodies trastuzumab, rituximab, cetuximab and bevacizumab have proven benefit both advanced early stage cancers. Furthermore impressive new technologies such as gene profiling, circulating tumour cells proteomics becoming major tools for prognostic assessment prediction of response to certain treatments. Whilst this is certainly good news patients it comes at price, many these very expensive may result unprecedented inequalities the delivery cancer care. largest impact be on developing countries, but starting felt some developed nations. Strategies tackle resource implications need addressed alongside development technologies.